Hiv Infection
Long-acting injectable effective, well tolerated in patients with HIV regardless of race
WASHINGTON — Studies of long-acting cabotegravir plus rilpivirine demonstrated high efficacy, safety and patient satisfaction regardless of patient race, according to data presented at IDWeek.
Model shows interventions could narrow life expectancy gap between Black, white MSM
WASHINGTON — Using a simulation model, researchers estimated that regular testing and improved engagement in care could add more than 3 years to the life expectancy of HIV-positive Black men who have sex with men.
Injection drug users with HCV history at risk for additional infections
An outbreak study based in West Virginia showed that people who inject drugs and have had hepatitis C are at risk for additional complications of injection drug use, including HIV hepatitis A and hepatitis B infection.
ALLIANCE trial delivers important treatment data for people with HIV, HBV coinfection
Treatment with bictegravir/emtricitabine/tenofovir alafenamide resulted in high HIV and hepatitis B virus suppression among adults with HIV and HBV coinfection, according to results from the ALLIANCE trial.
UNAIDS: Urgent action needed as global crises undermine HIV/AIDS response
In its annual report, UNAIDS said urgent action is needed to get the fight against HIV/AIDS back on track after it was derailed by “overlapping crises,” leaving up to 4,000 people with new HIV infections every day.
Nearly 9% of people prescribed PrEP abandoned their prescriptions in 2019
The first study to assess PrEP abandonment at retail pharmacies in the United States found that almost 9% of patients aged 16 years or older failed to pick up their prescriptions in 2019.
Top in cardiology: COVID-19-related cardiac complications, high BP during pregnancy
In the top story in cardiology last week, researchers reported that patients hospitalized with COVID-19 developed persistent dyspnea a year after discharge. These patients had no history of heart or lung disease.
HIV infection associated with 68% increased risk for HF
Individuals with HIV were at elevated risk for developing HF compared with individuals without HIV, according to new research published in Mayo Clinic Proceedings.
Risk reduction, increased screening for HCV in MSM is cost saving, effective
Long-acting ART safe, effective at 124 weeks
Long-acting injectable cabotegravir plus rilpivirine effectively maintained viral suppression of HIV among adults with or without a 1-month oral lead-in phase, according to the results of a study published in The Lancet HIV.